Most Read Articles
Rachel Soon, 4 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.

Drug survival higher for ixekizumab vs secukinumab in moderate-to-severe plaque psoriasis

11 Jul 2019

More patients with moderate-to-severe plaque psoriasis discontinued treatment with secukinumab despite receiving significantly fewer biologics prior to initiating this drug as compared with those treated with ixekizumab, a recent study has shown.

Secukinumab and ixekizumab were administered to 368 and 62 patients, respectively. The corresponding proportion of bionaive patients was 40.7 percent and 12.9 percent. In addition, patients treated with ixekizumab had been given significantly more biologics in the past.

Of the bionaive patients, 23.5 percent in the secukinumab arm and none in the ixekizumab arm discontinued therapy over 12 months. Drug survival for bionaive and non-naïve patients was higher for ixekizumab than for secukinumab.

During the maximum follow-up of 3 years, drug survival among secukinumab users was lowest for those who have previously received two or more biologics, followed by those who received secukinumab as their second-ever biologic.

In this study, the authors used the DERMBIO registry to examine the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with moderate-to-severe psoriasis in Denmark. Danish patients receiving treatment with either drug based on standard in-label dosing were included in the analysis. Survival curves were presented using Kaplan-Meier plots.

The study was limited by its relatively small sample size and the short follow-up duration.

“Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 4 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.